Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer

In our analysis, supplemental therapies did not offer an improvement in PCSM compared with BT alone for FIR or UIR prostate cancers. Further prospective clinical trials are required to determine whether BT monotherapy may be sufficient for a subset of patients with UIR disease.